Analytical Data
-
Gene name
CDKN2C
-
简介
The CDKN2C protein (also known as p18) interacts strongly with CDK6 and weakly with CDK4. Its functional effects inhibit cell growth and proliferation and are significantly related to the presence of endogenous retinoblastoma protein RB. CDKN2C Protein, Human (His) is the recombinant human-derived CDKN2C protein, expressed by E. coli , with N-6*His labeled tag.
- Application
-
Alternative Names
rHuCyclin-dependent kinase 4 inhibitor C/CDKN2C, His; Cyclin-Dependent Kinase 4 Inhibitor C; Cyclin-Dependent Kinase 6 Inhibitor; p18-INK4c; p18-INK6; CDKN2C; CDKN6
-
Species
Human
-
Source
E. coli
-
Tag
N-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P42773
-
Expression Region
M1-Q168
-
Protein Length
Full Length
-
Molecular Weight
17.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDKN2C, a member of the CDK inhibitor family, plays a critical role in cell cycle regulation by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), thereby preventing the progression from the G1 phase to the S phase of the cell cycle. Mutations and deletions in the CDKN2C gene have been implicated in various cancers, particularly in gliomas and certain types of leukemia, underscoring its significance as a tumor suppressor. Recent studies have focused on the role of CDKN2C in maintaining genomic stability and its interactions with other oncogenic pathways, revealing its potential as a therapeutic target. The recombinant protein of CDKN2C provides a valuable tool for further exploring its functional mechanisms, interactions, and effects on cell proliferation and apoptosis. This research is essential for understanding the complexities of tumorigenesis and developing targeted therapies that could enhance patient outcomes in cancers associated with CDKN2C dysregulation. Through the study of CDKN2C recombinant protein, scientists aim to elucidate the molecular pathways that govern cell cycle control and cancer progression, paving the way for innovative treatment strategies that leverage the tumor-suppressive properties of this vital protein.
